Anika Therapeutics Inc. (ANIK)

Schlusskurs vom Vortag:

$26.08

Offen:

$26.2

24-Stunden-Volumen:

34,060

Marktkapitalisierung:

$378.13M

Einnahmen:

$166.66M

Nettoeinkommen (Verlust:

$-82.67M

KGV:

-16.67

EPS:

-1.53

Netto-Cashflow:

$-7.22M

1W Leistung:

+0.95%

1M Leistung:

-0.04%

6M Leistung:

+21.78%

1J Leistung:

+0.08%

1-Tages-Spanne:

$25.50

$26.27

52-Wochen-Spanne:

$16.54

$28.67

Anika Therapeutics Inc. Stock (ANIK) Company Profile

Firmenname

Anika Therapeutics Inc.

Sektor

Healthcare (1211)

Branche

Medical Instruments & Supplies (60)

Telefon

781-457-9000

Adresse

32 Wiggins Avenue, Bedford, MA

Mitarbeiter

123

Twitter

Nächster Verdiensttermin

2024-06-13

Neueste SEC-Einreichungen

ANIK's Discussions on Twitter

Anika Therapeutics Inc. Stock (ANIK) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-03-07	Herabstufung	Barrington Research	Outperform → Mkt Perform
2022-11-09	Hochstufung	Barrington Research	Mkt Perform → Outperform
2022-10-14	Fortgesetzt	Stephens	Equal-Weight
2022-03-09	Herabstufung	Barrington Research	Outperform → Mkt Perform
2022-03-09	Herabstufung	Stephens	Overweight → Equal-Weight
2021-11-16	Eingeleitet	Stephens	Overweight
2021-07-16	Eingeleitet	UBS	Neutral
2020-12-16	Hochstufung	Barrington Research	Mkt Perform → Outperform
2020-05-08	Herabstufung	Barrington Research	Outperform → Mkt Perform
2020-01-21	Hochstufung	Sidoti	Neutral → Buy
2020-01-10	Hochstufung	First Analysis Sec	Outperform → Strong Buy
2019-11-05	Eingeleitet	BWS Financial	Sell
2019-09-24	Bestätigt	Barrington Research	Outperform
2019-09-23	Herabstufung	First Analysis Sec	Strong Buy → Outperform
2019-07-25	Hochstufung	First Analysis Sec	Neutral → Strong Buy
2019-02-22	Herabstufung	First Analysis Sec	Outperform → Neutral
2019-02-22	Herabstufung	Sidoti	Buy → Neutral
2018-07-27	Hochstufung	Barrington Research	Mkt Perform → Outperform
2018-06-20	Herabstufung	Barrington Research	Outperform → Mkt Perform
2018-06-20	Herabstufung	First Analysis Sec	Overweight → Equal-Weight
2018-05-04	Hochstufung	Barrington Research	Mkt Perform → Outperform
2018-02-23	Herabstufung	Barrington Research	Outperform → Mkt Perform
2018-01-24	Hochstufung	First Analysis Sec	Equal-Weight → Overweight
2017-10-27	Bestätigt	Barrington Research	Outperform
2016-05-09	Hochstufung	Singular Research	BUY - Long-Term → Buy
2016-04-27	Herabstufung	Northland Capital	Outperform → Market Perform
2016-02-26	Bestätigt	Barrington Research	Outperform

Alle ansehen

Anika Therapeutics Inc. Aktie (ANIK) Neueste Nachrichten

Pendopharm renews distribution agreement with Anika Therapeutics Inc. for Cingal®, Monovisc®, and Orthovisc® - Canada NewsWire

Canada NewsWire

Why You Shouldn't Bet Against Anika Therapeutics (ANIK) Stock? - Yahoo News UK

Yahoo News UK

Research Analysts Set Expectations for Anika Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ANIK) - MarketBeat

MarketBeat

Anika Therapeutics (NASDAQ:ANIK) Receives Outperform Rating from Barrington Research - Defense World

Defense World

Investors in Anika Therapeutics (NASDAQ:ANIK) have unfortunately lost 52% over the last five years - Yahoo Lifestyle UK

Yahoo Lifestyle UK

New Report Orthopedic Regenerative Medicine Market|Ortho Regenerative Technologies Inc, Personalized stem cells ... - Motions Online

Motions Online

Finanzdaten der Anika Therapeutics Inc.-Aktie (ANIK)

Anika Therapeutics Inc. (ANIK) Umsatz 2024

Anika Therapeutics Inc. (ANIK) Nettogewinn 2024

Anika Therapeutics Inc. (ANIK) Free Cashflow 2024

Anika Therapeutics Inc. (ANIK) Gewinn je Aktie 2024